Mochida Pharmaceutical Co., Ltd.
Consolidated Financial Summary for the Third Quarter of Fiscal Year Ending March 2026 (Japanese GAAP)
For the third quarter of the fiscal year ending March 2026, net sales were ¥87,487 million (up 8.4% YoY), operating income was ¥7,526 million (up 3.9% YoY), and net income attributable to owners of parent was ¥6,342 million (up 13.2% YoY), demonstrating steady business performance.
Key Figures
- Net Sales: ¥87,487 million (up 8.4% Year-over-Year)
- Operating Income: ¥7,526 million (up 3.9% Year-over-Year)
- Net Income Attributable to Owners of Parent: ¥6,342 million (up 13.2% Year-over-Year)
AI要約
Overview of Business Performance
In the consolidated cumulative third quarter period of the fiscal year ending March 2026, Mochida Pharmaceutical Co., Ltd. reported net sales of ¥87,487 million (up 8.4% YoY), operating income of ¥7,526 million (up 3.9% YoY), ordinary income of ¥8,346 million (up 9.2% YoY), and net income attributable to owners of parent of ¥6,342 million (up 13.2% YoY). The pharmaceutical-related business saw increased sales year-over-year driven by growth in new drugs, while the healthcare business also posted an 8.2% increase in net sales. R&D expenses amounted to ¥8,984 million, with ongoing development focused on nucleic acid and cell medicines.
Financial Position and Revision of Earnings Guidance
Total assets increased to ¥182,220 million compared to the end of the previous fiscal year, and net assets also rose to ¥137,431 million, while the equity ratio declined to 75.4%. The number of outstanding shares remained unchanged at 36,390,000 shares. The consolidated earnings forecast for the fiscal year ending March 2026 was revised to project net sales of ¥115,500 million (up 9.8% YoY), operating income of ¥9,500 million (up 16.9% YoY), and net income attributable to owners of parent of ¥8,400 million (up 47.8% YoY).
